Hjem › Hemofili
Kliniske studier for Hemofili rekrutterer i USA
28 studier for Hemofili rekrutterer deltakere på steder over hele USA.
Byer med flest studier
- Indianapolis, IN9 studier
- Los Angeles, CA7 studier
- Seattle, WA6 studier
- Cedar Rapids, IA6 studier
- Philadelphia, PA5 studier
- Tampa, FL4 studier
- Sacramento, CA4 studier
- Atlanta, GA4 studier
- Little Rock, AR4 studier
- Dallas, TX4 studier
- Greenville, NC4 studier
- Orange, CA4 studier
- San Francisco, CA3 studier
- San Antonio, TX3 studier
- St. Louis, MO3 studier
- Detroit, MI3 studier
- Chicago, IL3 studier
- Boston, MA3 studier
- Cincinnati, OH3 studier
- Harrisburg, PA3 studier
- Kansas City, MO3 studier
- Aurora, CO3 studier
Etter delstat
- Arkansas4 studier
- California14 studier
- Colorado3 studier
- Florida6 studier
- Georgia4 studier
- Illinois4 studier
- Indiana9 studier
- Iowa6 studier
- Massachusetts3 studier
- Michigan5 studier
- Missouri5 studier
- New York4 studier
- North Carolina6 studier
- Ohio5 studier
- Pennsylvania6 studier
- Texas8 studier
- Washington6 studier
Nylig oppdaterte studier
Offisiell studietekst (engelsk)
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
RekruttererFase 3
Alder 18 og eldre · Menn · Oppdatert 2. okt. 2026 · NCT05568719TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies
RekruttererObservasjonsstudie
6 Months · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07692217Treatment of Hemophilia A Patients With FVIII Inhibitors
RekruttererObservasjonsstudie
Alle aldre · Menn · Oppdatert 23. sep. 2026 · NCT04023019A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
RekruttererFase 3
Alder 12 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07416526A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RekruttererFase 3
Alder 1 til 17 · Menn · Oppdatert 23. sep. 2026 · NCT05611801A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
RekruttererFase 4
Alder 12 og eldre · Menn · Oppdatert 23. sep. 2026 · NCT06145373A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
Alder 18 til 64 · Menn · Oppdatert 18. sep. 2026 · NCT07220564A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RekruttererFase 1/2
Alder 2 til 59 · Menn · Oppdatert 11. sep. 2026 · NCT05987449A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RekruttererFase 1/2
Alder 18 og eldre · Menn · Oppdatert 11. sep. 2026 · NCT07226206A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
RekruttererFase 3
Alder 12 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT07416604SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
RekruttererFase 3
Alder 6 og eldre · Alle kjønn · Oppdatert 21. aug. 2026 · NCT04563520Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 0 til 20 · Alle kjønn · Oppdatert 21. aug. 2026 · NCT04278404ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT04398628A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
RekruttererFase 3
Alder 1 til 11 · Menn · Oppdatert 17. aug. 2026 · NCT07285460Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
RekruttererObservasjonsstudie
Alder 6 til 19 · Alle kjønn · Oppdatert 2. jul. 2026 · NCT05022459A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
Alder 18 til 60 · Alle kjønn · Oppdatert 2. jul. 2026 · NCT06349473Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RekruttererFase 3
Alder 1 til 74 · Menn · Oppdatert 1. jul. 2026 · NCT05145127A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
RekruttererFase 1
Alder 12 til 74 · Menn · Oppdatert 3. jun. 2026 · NCT06703606Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 2. jun. 2026 · NCT03695978Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RekruttererFase 4
Alder 12 og eldre · Kvinner · Oppdatert 12. mai 2026 · NCT05936580Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
RekruttererFase 4
Alder 12 og eldre · Menn · Oppdatert 12. mai 2026 · NCT05935358ATHNdataset Registry
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 21. apr. 2026 · NCT06820515Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
RekruttererFase 1
Alder 0 til 90 · Alle kjønn · Oppdatert 3. apr. 2026 · NCT05500807Hemophilia A Research Program
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alle aldre · Alle kjønn · Oppdatert 17. feb. 2026 · NCT07414511SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
RekruttererFase 4
Alder 12 til 100 · Alle kjønn · Oppdatert 12. jan. 2026 · NCT04647227Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.